Informatics Publishing Limited

Prerna Dubey ¹, M. Sumithra ¹, V. Chitra ¹

Affiliations
1 Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology Kattankulathur 603203, Tamil Nadu, IN

Abstract

Inflammatory bowel diseases (IBD) termed as chronic inflammatory disorders of the gastrointestinal tract distinct by episodes of reversion and decline. The two identified subtypes of the disease, ulcerative colitis and Crohn's Disease which differ in forms of clinical presentation. Environmental factors, including infections, diet, lifestyle factors, medication use have contributed to alterations in the global prevalence of the disease. Although the exact pathogenesis of IBD remains unknown, part of the underlying mechanism is a deregulated host immune response to intestinal flora, in genetically vulnerable Beings. The incidence of IBD is persistently rising in other earlier low incidence areas, such as Asia and the developing world. The annual frequency of CD is highest in North America (20.2 per 100,000, per person-years); whereas the annual occurrence of UC is highest in Europe (24.3 per 100,000 per person-years) Environmental risk factors of IBD is smoking, air water pollution, vitamin D, dietary, NSAID, stress. The newly described Th17 cells are also involved in the gut inflammatory answer in IBD. To understand the pathogenesis of IBD alternative model has been used such as zebrafish, c. elegans, Drosophila. The novel treatment of IBD such as vedolizumab, Etrolizumab, agents targeting specific pathways in IBD, but unfortunately possess life-threatening adverse effect and globally increased cost. This review also focuses on the favourable results from the use of herbal products in the treatment of IBD.

Keywords

Ulcerative, Colitis, Crohn’s, Antioxidant, Vedolizumab, Pathogenesis.

Full Text

     

Prerna Dubey ¹, Rukaiah Fatma Begum ², V. Chitra ², R. Mrinalini ², Harini Gunasekaran ³, M. Sumithra ²

Affiliations
1 QVIA RDS (India) Private Limited, Bangalore – 560103, Karnataka, IN
2 Department of Pharmacology, SRM College of Pharmacy, SRMIST, Kattankulathur, Chengalpattu – 603203, Tamil Nadu, IN
3 Labcorp Scientific Services and Solutions Private Limited, Mumbai – 400093, Maharashtra, IN

Abstract

The pharmacological healing for inflammatory bowel diseases continues to be uncertain and requires immediate therapeutic interventions. A poly-herbal formulation obtained from a traditional and authentic classic text of Ayurveda was assessed for its effect against IBD (inflammatory bowel disease) in this study. The formulated poly-herbal suspension comprises three different drugs namely, Burma dhaniya (Eryngium foetidum), Sapota (Manilkara zapota), and Curry leaves (Murraya koenigii). The formulated suspension was evaluated for certain standard parameters like organoleptic and accelerated stability studies at various temperatures. It was checked for its efficacy by oral route in acetic acid-induced colitis affected Balb/c mice. Mice were orally administered with formulated suspension (275 mg/kg, 550 mg/kg,), every 24 hours for 10 days. Histopathology, macroscopic damage score, myeloperoxidase (MPO) activity, and red blood cell parameters were evaluated after treatment. Reduction in the MPO activity, decrease in the macroscopic damage scores, and an increase in RBC cell count were seen distinctly at a high dose of 550 mg/Kg. The results obtained, established the effectiveness of the poly-herbal suspension against inflammatory bowel disease by treating the mice from acetic acid-induced colitis by reducing inflammation and oxidative damage to the colon. The maximum therapeutic effective activity was found to be 550 mg/kg for IBD mice.

Keywords

Acetic Acid, Inflammatory Bowel Disease, Myeloperoxidase, Polyherbal Suspension, Ulcerative Colitis.

Full Text